External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry - Université de Limoges Accéder directement au contenu
Article Dans Une Revue European Heart Journal Année : 2018

External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry

Résumé

The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial.

Dates et versions

hal-02043611 , version 1 (21-02-2019)

Identifiants

Citer

Arthur Darmon, Deepak Bhatt, Yedid Elbez, Victor Aboyans, Sonia Anand, et al.. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal, 2018, 39 (9), pp.750-757a. ⟨10.1093/eurheartj/ehx658⟩. ⟨hal-02043611⟩
38 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More